Quick Takeaways:
- Parnell has acquired Noble Pharma, strengthening its US operations and expanding its manufacturing capabilities
- The acquisition enhances supply continuity and supports growth across Parnell’s portfolio, leveraging Noble Pharma’s FDA and DEA-accredited manufacturing expertise
- With this move, Parnell aims to scale production, accelerate innovation, and better serve its growing customer base in the US market
Why It Matters?
Parnell is bolstering its US footprint by buying Noble Pharma, adding an FDA and DEA‑accredited plant in Wisconsin with broad dosage-form capabilities to secure supply and support portfolio growth.
The acquisition turns Noble’s CDMO-style operation, spanning liquids, suspensions, tablets, boluses, powders, gels, pastes, creams, and ointments, into an internal and third‑party manufacturing engine, allowing Parnell to scale production, improve reliability for customers, and accelerate innovation in the US market.
Source: Businesswire
